Business Context and Reporting Period
Company: China Pharma Holdings, Inc. (CPHI)
Filing Type: Form 8-K (Current Report)
Date of Report: December 22, 2025
Event: Entry into a Material Definitive Agreement for technology transfer.
Key Financial Metrics and Transaction Details
This filing reports a specific transaction rather than periodic financial performance. Key metrics related to the transaction include:
- Transaction Value: $9.8 million.
- Consideration: Issuance of 7,000,000 restricted shares of Common Stock.
- Implied Share Price: $1.40 per share.
- Asset Acquired: Invention patent for Ipragliflozin tablets and Method for Its Preparation.
- Counterparty: Juan Zhang (Transferor).
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reporting period.
Material Changes and Transaction Structure
The Company's wholly owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., entered into a Technology Transfer Agreement. The Transferor will transfer patent ownership to the subsidiary and provide technical services, including product R&D and registration application support. The transaction involves the issuance of unregistered equity securities.
Guidance, Risks, and Regulatory Status
- Regulatory Exemption: The 7,000,000 shares are being issued in reliance on the exemption from registration under Regulation S of the Securities Act, as the transaction was negotiated and consummated outside the United States with a non-U.S. person.
- Share Status: The issued shares are restricted.
- Outlook: The filing does not contain forward-looking guidance, management commentary on future earnings, or specific risk factors beyond the standard regulatory disclosures for unregistered securities.
Investor Verification Checklist
- Verify the validity and enforceability of the Ipragliflozin patent being transferred.
- Confirm the regulatory status of the 7,000,000 restricted shares and any lock-up periods.
- Assess the commercial viability and development timeline of the Ipragliflozin tablets.
- Review the Company's current cash position to ensure it can support the R&D and registration costs associated with the new technology.
- Check for any subsequent filings regarding the actual issuance of the shares.